CC Share Price | The Chemours Co. Stock Analysis & Recommendation

Q: What does The Chemours Co. do?

Overview: The Chemours Co. is a provider of performance chemicals in the specialty chemicals industry, operating within the small-cap market.Financial Snapshot: Most recent Net Sales: 1,368 Million (Quarterly Results - Mar 2025) Most recent Net Profit: -4 Million (Quarterly Results - Mar 2025) Market-cap: USD 1,905.97 Million (Small Cap)Key Metrics: P/E: 12.00 Dividend Yield: 391.10% Debt Equity: 6.35 Return on Equity: 28.67% Price to Book: 3.29Contact Details: Address: 1007 Market St, WILMINGTON DE: 19898-1100 Tel: 1 302 7731000 Fax: 1 302 6555049 Website: https://www.chemours.com/

Q: Who are in the management team of The Chemours Co.?

As of March 2022, the management team of The Chemours Co. includes the following individuals:- Mr. Richard Brown, who serves as the Independent Chairman of the Board.- Mr. Mark Vergnano, who is the President, Chief Executive Officer, and Director.- Mr. Curtis Anastasio, serving as an Independent Director.- Mr. Bradley Bell, also an Independent Director.- Ms. Mary Cranston, who is an Independent Director.- Dr. Curtis Crawford, serving as an Independent Director.- Ms. Dawn Farrell, who is an Independent Director.This team is responsible for guiding the company's strategic direction and governance.

Q: Is The Chemours Co. overvalued or undervalued?

As of 5 August 2025, The Chemours Co. has moved from a very attractive to a risky valuation grade. The company appears to be overvalued given its current metrics. The P/E ratio stands at 12, while the EV to EBITDA ratio is 7.55, and the PEG ratio is exceptionally low at 0.06, indicating potential overvaluation relative to growth expectations.In comparison to its peers, The Chemours Co. has a P/E ratio that is significantly lower than Westlake Corp. at 82.20 and Albemarle Corp. which has a negative P/E ratio. This suggests that while Chemours may be facing challenges, its valuation metrics are not as favorable as some competitors. Additionally, the company's recent stock performance shows a decline of 5.14% over the past year, contrasting sharply with the S&P 500's gain of 17.14%, further reinforcing the notion of overvaluation.

Q: Is The Chemours Co. technically bullish or bearish?

As of 3 October 2025, the technical trend has changed from bullish to mildly bullish. The current stance is mildly bullish, supported by a bullish MACD on the weekly timeframe and a bullish moving average on the daily timeframe. However, the monthly MACD is only mildly bullish, and the Bollinger Bands indicate a mildly bearish outlook for the monthly period. The KST shows a bullish signal weekly but bearish monthly, while the OBV is mildly bullish monthly. In terms of performance, Chemours has underperformed the S&P 500 significantly over longer periods, with a year-to-date return of -6.51% compared to the S&P's 14.18%, and a 1-year return of -17.84% versus the S&P's 17.82%.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

9.29 M

Shareholding (Dec 2025)

FII

13.07%

Held by 150 FIIs

DII

25.75%

Held by 78 DIIs

Promoter

0.00%

How big is The Chemours Co.?

22-Jun-2025

As of Jun 18, The Chemours Co. has a market capitalization of $1.91 billion, with net sales of $5.80 billion and a net profit of $31 million for the latest four quarters. The balance sheet shows shareholder's funds of $604 million and total assets of $7.52 billion.

View full answer

What does The Chemours Co. do?

22-Jun-2025

The Chemours Co. is a small-cap provider of performance chemicals in the specialty chemicals industry, with recent net sales of $1.368 billion and a market cap of approximately $1.906 billion. Key metrics include a P/E ratio of 12.00 and a dividend yield of 391.10%.

View full answer

Who are in the management team of The Chemours Co.?

22-Jun-2025

As of March 2022, The Chemours Co. management team includes Independent Chairman Richard Brown, CEO Mark Vergnano, and Independent Directors Curtis Anastasio, Bradley Bell, Mary Cranston, Curtis Crawford, and Dawn Farrell, who oversee the company's strategic direction and governance.

View full answer

Is The Chemours Co. overvalued or undervalued?

20-Sep-2025

As of August 5, 2025, The Chemours Co. is considered overvalued with a P/E ratio of 12 and a decline of 5.14% in stock performance over the past year, contrasting with the S&P 500's 17.14% gain, indicating a shift from a very attractive to a risky valuation grade.

View full answer

Is The Chemours Co. technically bullish or bearish?

07-Oct-2025

As of October 3, 2025, Chemours shows a mildly bullish trend with mixed indicators, underperforming the S&P 500 significantly year-to-date and over the past year.

View full answer

Compare The Chemours Co. with Similar Stocks

NewMarket Corp.ChampionX Corp.Celanese Corp.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

High Debt company with Weak Long Term Fundamental Strength

Poor long term growth as Net Sales has grown by an annual rate of 2.72% and Operating profit at 2.17% over the last 5 years
High Debt Company with a Debt to Equity ratio (avg) at times

Negative results in Jun 25

Risky -

Consistent Underperformance against the benchmark over the last 3 years

Mojo Parameters

Stock DNA

Industry

Specialty Chemicals

Market cap

USD 3,138 Million (Small Cap)

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

1.67%

Debt Equity

13.88

Return on Equity

-4.80%

Price to Book

12.55

Revenue and Profits:

Net Sales:

1,330 Million

(Quarterly Results - Dec 2025)

Net Profit:

-62 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

49.12%

6 Months

0.97%

1 Year

20.98%

2 Years

-36.33%

3 Years

-38.26%

4 Years

-41.18%

5 Years

-34.03%

The Chemours Co. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

3.06%

EBIT Growth (5y)

-7.58%

EBIT to Interest (avg)

2.41

Debt to EBITDA (avg)

8.11

Net Debt to Equity (avg)

6.35

Sales to Capital Employed (avg)

1.26

Tax Ratio

49.18%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

100.00%

ROCE (avg)

12.26%

ROE (avg)

33.84%

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

12.55

EV to EBIT

22.02

EV to EBITDA

11.82

EV to Capital Employed

1.78

EV to Sales

1.14

PEG Ratio

Dividend Yield

1.67%

ROCE (Latest)

8.07%

ROE (Latest)

-4.80%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bullish

Mildly Bullish

RSI

No Signal

Bollinger Bands

Bullish

Mildly Bullish

Moving Averages

Bullish (Daily)

KST

Bullish

Mildly Bullish

Dow Theory

Mildly Bullish

No Trend

OBV

Mildly Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Dec 2025

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 77 Schemes (61.1%)

Foreign Institutions

Held by 150 Foreign Institutions (13.07%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Dec 2025 is -11.04% vs -7.43% in Sep 2025",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Dec 2025 is -203.33% vs 115.79% in Sep 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Sep'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "1,330.00",
          "val2": "1,495.00",
          "chgp": "-11.04%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "95.00",
          "val2": "178.00",
          "chgp": "-46.63%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "68.00",
          "val2": "67.00",
          "chgp": "1.49%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-25.00",
          "val2": "-8.00",
          "chgp": "-212.50%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-62.00",
          "val2": "60.00",
          "chgp": "-203.33%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "10.50%",
          "val2": "65.60%",
          "chgp": "-5.51%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2025 is 0.45% vs -4.87% in Dec 2024",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2025 is -659.42% vs 129.11% in Dec 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "5,808.00",
          "val2": "5,782.00",
          "chgp": "0.45%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "654.00",
          "val2": "735.00",
          "chgp": "-11.02%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "268.00",
          "val2": "264.00",
          "chgp": "1.52%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-384.00",
          "val2": "-110.00",
          "chgp": "-249.09%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-386.00",
          "val2": "69.00",
          "chgp": "-659.42%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "54.10%",
          "val2": "75.10%",
          "chgp": "-2.10%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQ

Dec'25

Sep'25

Change(%)

Net Sales

1,330.00

1,495.00

-11.04%

Operating Profit (PBDIT) excl Other Income

95.00

178.00

-46.63%

Interest

68.00

67.00

1.49%

Exceptional Items

-25.00

-8.00

-212.50%

Consolidate Net Profit

-62.00

60.00

-203.33%

Operating Profit Margin (Excl OI)

10.50%

65.60%

-5.51%

USD in Million.

Compare with Peers

Net Sales

QoQ Growth in quarter ended Dec 2025 is -11.04% vs -7.43% in Sep 2025

Consolidated Net Profit

QoQ Growth in quarter ended Dec 2025 is -203.33% vs 115.79% in Sep 2025

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'25

Dec'25

Dec'24

Change(%)

Net Sales

5,808.00

5,782.00

0.45%

Operating Profit (PBDIT) excl Other Income

654.00

735.00

-11.02%

Interest

268.00

264.00

1.52%

Exceptional Items

-384.00

-110.00

-249.09%

Consolidate Net Profit

-386.00

69.00

-659.42%

Operating Profit Margin (Excl OI)

54.10%

75.10%

-2.10%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2025 is 0.45% vs -4.87% in Dec 2024

Consolidated Net Profit

YoY Growth in year ended Dec 2025 is -659.42% vs 129.11% in Dec 2024

All Annual Results

Company CV

About The Chemours Co.

The Chemours Co.

Specialty Chemicals

The Chemours Co is a provider of performance chemicals. The Company provides a range of industrial and specialty chemicals products for markets, including plastics and coatings, refrigeration and air conditioning, general industrial, electronics, mining, and oil refining. Its segments include Fluoroproducts segment, Chemical Solutions segment and Titanium Technologies segment. Fluoroproducts segment is a provider of fluorine-based, advanced materials solutions, such as refrigerants and industrial resins and derivatives. Chemical Solutions segment is comprised of a portfolio of industrial chemical businesses, primarily operating in the Americas. Titanium Technologies segment is a manufacturer of TiO2 pigment. The Company serves various industries, such as electronics, communications, automotive, wire and cable, energy, oil and gas, and aerospace.

Company Coordinates

Company Details

1007 Market St , WILMINGTON DE : 19898-1100

Tel: 1 302 7731000

https://www.chemours.com/

Registrar Details